Etoricoxib is a new COX-2 selective inhibitor. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2). This reduces the generation of prostaglandins (PGs) from arachidonic acid.
ETORICOXIB
Structure
Product Description
Details |
|
|---|---|
Chemical Name |
ETORICOXIB |
IUPAC Name |
5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]- 2,3'-bipyridine |
CAS Number |
202409-33-4 |
Molecular Formula |
C18H15CIN2O2S |
Synonyms |
Algix;Etoxib;Etocox;MK 663;Tauxib;Etobrix;Arcoxia;Kingcox;MK 0663;Etropain |
Application |
For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. |